FOR IMMEDIATE RELEASE
November 3, 2004
John R. La Montagne, Ph.D., deputy director of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), died suddenly in Mexico City on November 2, 2004. He was 61.
“All of us are profoundly saddened by the loss of John La Montagne,” said NIAID Director Anthony S. Fauci, M.D. “Personally, he was a dear friend and one of the finest people I have ever known. Professionally, in an NIH career spanning nearly 30 years, his leadership and commitment to improving global health were remarkable. His generosity, wit, even-handedness and kindness made him a friend to all who knew him. He will be sorely missed.”
Tommy G. Thompson, Secretary of the Department of Health and Human Services, the parent agency of NIH, said, “We mourn the passing of John La Montagne, a true public health hero whose leadership, especially in the realm of infectious diseases, left the world a healthier place. His passing is a tremendous loss for all of us.”
Elias A. Zerhouni, M.D., NIH Director, said, “John La Montagne devoted his life to improving the health of children and adults here and abroad. His leadership and counsel have been invaluable in NIH research efforts to fight emerging and re-emerging diseases, including biodefense research activities. I count myself lucky to have known and worked with John.”
Dr. La Montagne, a native of Mexico City, Mexico, received his Ph.D. from Tulane University in 1971. In 1976, he came to NIH as the Influenza Program Officer at the NIAID. He became the Program Officer for the Viral Vaccines Program in 1983, and the Influenza and Viral Respiratory Diseases Program Officer in 1984. Beginning in 1986, Dr. La Montagne assumed the role of Director of the AIDS Program. In 1987 he was appointed Director of the Microbiology and Infectious Diseases Program, which became a Division in 1988. Dr. La Montagne was appointed Deputy Director of the NIAID in February 1998.
Dr. La Montagne made significant contributions to the national and international effort against emerging and re-emerging infectious diseases, including biodefense-related activities, and has been recognized internationally for his leadership in this area. He played a central role in the organization of the Multilateral Initiative on Malaria, an international effort involving research, control, and development agencies from the U.S., Europe, and Africa. In addition, he served as a member of the Scientific Advisory Groups of Experts on Vaccines and Biologicals as well as for Vaccines and Immunization for the World Health Organization. He chaired the WHO Task Force on Strategic Planning for the Children’s Vaccine Initiative, advised the Pan American Health Organization on their programs in vaccine research implementation, and served as a member of the board of the Global Alliance for Tuberculosis Drug Development. Dr. La Montagne also served as a member of the Biomedical Research Confederation Executive Steering Committee at Ft. Detrick, Maryland, and as co-chair of the Research and Development Gaps Working Group, a component of the Weapons of Mass Destruction Subcommittee of the National Science and Technology Council. His outstanding administrative leadership at NIH included membership on the NIH Community Advisory Board for Security and the recently formed NIH Ethics Advisory Committee.
As an influential contributor to the field of infectious diseases, Dr. La Montagne delivered numerous major lectures all over the world. He received many prestigious awards for his scientific accomplishments, including the PHS Special Recognition Award for leadership in childhood vaccine research programs, the Surgeon General’s Certificate of Appreciation, the Presidential Meritorious Executive Rank Award, the Distinguished Executive Award for his work in the areas of infectious diseases research of global health relevance, the Secretary’s Award for Distinguished Service for leadership of acellular pertussis vaccine trials, and most recently the Secretary’s Award for Distinguished Service for design and implementation of critically important biodefense strategies.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of
infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News
releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research,
and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health ®
back to top
Last Updated November 03, 2004